Hunting for clues


One in three adults die of cancer and the treatment of many solid epithelial malignant tumors remains disappointing. Colorectal cancer (CRC) is one of the most common tumors diagnosed in the developed world. The mainstay of treatment is surgical excision, with adjuvant chemotherapy if the tumor has already spread beyond the confines of the bowel wall or is deemed aggressive following histological examination, for instance, with vascular invasion. There is a huge global effort directed at discovering better treatments for cancer. One potentially fruitful but as yet unfulfilled approach is to utilize the hosts’ immune system to generate effective anti-tumor responses leading to control or destruction of the cancer. One of the oldest clinical demonstrations of this approach was the instillation of intravesicular bacillus Calmette-Guerin (BCG) to control bladder cancer. However the oncology field has been filled with scepticism for several reasons, including the failure of the vast majority of clinical immunotherapy trials and indeed, the paucity of demonstrable anti-tumor immune responses in cancer patients often questioned their very existence. One of many reasons for these disappointments may be the activities of a population of natural regulatory T cells (T regs ), which appear to inhibit not only auto-reactive T-cell responses, helping prevent autoimmune disease, but also those responses directed at tumors. Hunting for clues Regulatory T cells and colorectal cancer

Extracted Key Phrases

1 Figure or Table

Cite this paper

@inproceedings{Gallimore2012HuntingFC, title={Hunting for clues}, author={Awen M. Gallimore and Andrew J. Godkin}, year={2012} }